Madrigal Pharmaceuticals, Inc. MDGL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$94.39M-61.1% | -$58.58M+48.7% | -$114.19M-170% | -$42.28M+42.3% | -$73.24M-23.3% | ||
| $386K-1.5% | $392K+9.5% | $358K-5.0% | $377K-0.5% | $379K+4.4% | ||
| $34.02M+31.9% | $25.79M-1.8% | $26.25M+4.3% | $25.16M+20.2% | $20.93M+18.4% | ||
| $449K-4.1% | $468K+42.2% | $329K-11.3% | $371K-14.9% | $436K-9.5% | ||
| $52.88M+150% | $21.19M-37.8% | $34.05M+91.3% | $17.8M+134% | $7.61M-67.4% | ||
| $22.19M+1,183% | $1.73M-70.3% | $5.82M-29.5% | $8.26M-61.0% | $21.17M-16.5% | ||
| $3.58M-27.5% | $4.94M-17.1% | $5.96M+246% | -$4.08M-164% | -$1.54M— | ||
| $4.29M— | —— | $187.54M+463% | $33.31M+6,386% | -$530K— | ||
| $40.65M— | —— | —— | $35.36M+274% | $9.46M— | ||
| $2.44M— | —— | —— | -$942K— | $0— | ||
| -$167.44M-25.5% | -$133.46M— | —— | -$47.05M+47.1% | -$88.89M+14.9% | ||
| $3.85M— | —— | $857K— | $0— | $0-100% | ||
| $157.83M-25.9% | $212.96M-55.5% | $478.21M+112% | $225.53M+72.4% | $130.81M-62.6% | ||
| $353.87M+47.4% | $240.15M-12.7% | $275.07M+0.6% | $273.39M-7.2% | $294.69M-2.6% | ||
| $192.19M+597% | $27.58M— | —— | $47.86M-70.8% | $163.88M+442% | ||
| $2.33M— | —— | —— | —— | $8.64M— | ||
| $2.33M-74.0% | $8.96M-96.2% | $236.65M+13,493% | $1.74M-79.8% | $8.64M-56.3% | ||
| $1.32M— | —— | —— | —— | $0— | ||
| $28.41M— | —— | $109.5M+4,199% | $2.55M-97.0% | $83.63M— | ||
| $449K-4.1% | $468K+42.2% | $329K-11.3% | $371K-14.9% | $436K-9.5% | ||
| $3.58M-27.5% | $4.94M-17.1% | $5.96M+246% | -$4.08M-164% | -$1.54M— | ||
| $1.98M-17.6% | $2.4M+1,090% | $202K-60.6% | $513K-82.0% | $2.85M+121% | ||
| $40.65M— | —— | —— | $35.36M+274% | $9.46M— | ||
| $408K-73.6% | $1.55M-0.2% | $1.55M+2,720% | $55K-1.8% | $56K— | ||
| $2.44M— | —— | —— | -$942K— | $0— | ||
| $353.87M+47.4% | $240.15M-12.7% | $275.07M+0.6% | $273.39M-7.2% | $294.69M-2.6% | ||
| $2.98M— | —— | —— | —— | $0— | ||
| $1.67M— | —— | —— | $4M— | $0-100% | ||
| -$171.28M-28.7% | -$133.07M— | —— | -$47.05M+47.1% | -$88.89M+15.1% | ||
| -$171.28M-28.7% | -$133.07M— | —— | -$47.05M+47.1% | -$88.89M+15.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Madrigal Pharmaceuticals, Inc. generate?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
- What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
- After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
- Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
